Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib

BACKGROUND: Lenvatinib has been approved for use in the systemic treatment for unresectable hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy and safety of lenvatinib in patients with unresectable HCC who received sorafenib. METHODS: A total of 40 patients who received len...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Yang, Wang, Chih-Chi, Liu, Yueh-Wei, Li, Wei-Feng, Chen, Yen-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668202/
https://www.ncbi.nlm.nih.gov/pubmed/33240675
http://dx.doi.org/10.7717/peerj.10382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668202/
https://www.ncbi.nlm.nih.gov/pubmed/33240675
http://dx.doi.org/10.7717/peerj.10382

Ejemplares similares